Demographic and clinical characteristics of ≥1-year survivors of HCT
| Characteristics . | Training data set COH, N = 1828 . | CVD, N = 135 . | No CVD, N = 1693 . | P* . | Validation data set FHCRC, N = 580 . |
|---|---|---|---|---|---|
| Sex, n (%) | |||||
| Male | 1052 (57.5) | 82 (60.7) | 970 (57.3) | .44 | 319 (55.0) |
| Ethnicity/race, n (%) | |||||
| Non-Hispanic white | 1142 (62.5) | 93 (68.9) | 1049 (62) | 502 (86.6) | |
| Hispanic | 453 (24.8) | 22 (16.3) | 431 (25.5) | 41 (7.1) | |
| Other | 233 (12.7) | 20 (14.8) | 213 (12.6) | .06 | 37 (6.4) |
| Age, y† | |||||
| Median (range) | 45.0 (1.6-79.9) | 53.0 (17.0-79.9) | 44.2 (1.6-78.3) | <.001 | 45.0 (2.0-74.0) |
| <30, n (%) | 407 (22.3) | 9 (6.7) | 398 (23.5) | 131 (22.6) | |
| 30 to <50, n (%) | 756 (41.4) | 46 (34.1) | 710 (41.9) | 98 (16.9) | |
| ≥50, n (%) | 665 (36.4) | 80 (59.3) | 585 (34.6) | <.001 | 351 (60.5) |
| Diagnosis, n (%) | |||||
| Acute leukemia | 537 (29.4) | 34 (25.2) | 503 (29.7) | 211 (36.4) | |
| Chronic leukemia | 241 (13.2) | 13 (9.6) | 228 (13.5) | 124 (21.4) | |
| Lymphoma | 704 (38.5) | 64 (47.4) | 640 (37.8) | 118 (20.3) | |
| Other | 346 (18.9) | 24 (17.8) | 322 (19.0) | .15 | 127 (21.9) |
| Anthracycline dose, mg/m2 | |||||
| Median (range) | 180 (0-1116) | 225 (0-528) | 180 (0-1116) | .001 | 116 (0-972) |
| ≤250 mg/m2, n (%) | 1183 (64.7) | 70 (51.9) | 1113 (65.7) | 409 (70.5) | |
| >250 mg/m2, n (%) | 645 (35.3) | 65 (48.1) | 580 (34.3) | .001 | 165 (28.4) |
| Anthracycline use, n (%) | |||||
| Yes | 1376 (75.3) | 111 (82.2) | 1265 (74.7) | .05 | 327 (56.4) |
| Chest radiation, n (%) | |||||
| Yes | 97 (5.3) | 11 (8.1) | 86 (5.1) | .13 | 47 (8.1) |
| HCT type, n (%) | |||||
| Autologous | 1031 (56.4) | 95 (70.4) | 936 (55.3) | 191 (32.9) | |
| Allogeneic | 797 (43.6) | 40 (29.6) | 757 (44.7) | .001 | 389 (67.1) |
| Conditioning regimen, n (%) | |||||
| Chemotherapy only | 850 (46.5) | 63 (46.7) | 787 (46.5) | 264 (45.5) | |
| Chemotherapy + TBI | 978 (53.5) | 72 (53.3) | 906 (53.5) | .97 | 314 (54.5) |
| Cardiovascular risk factors,†n (%) | |||||
| Hypertension | 512 (28.0) | 67 (49.6) | 445 (26.3) | <.001 | 136 (23.4) |
| Diabetes | 198 (10.8) | 37 (27.4) | 161 (9.5) | <.001 | 48 (8.3) |
| Dyslipidemia | 600 (32.8) | 52 (38.5) | 548 (32.4) | .14 | 36 (6.2) |
| Smoking, ever | 558 (30.5) | 59 (43.7) | 499 (29.5) | .001 | 217 (37.4) |
| Obesity (BMI ≥30 kg/m2) | 442 (24.2) | 41 (30.4) | 401 (23.7) | .081 | 114 (19.7) |
| Characteristics . | Training data set COH, N = 1828 . | CVD, N = 135 . | No CVD, N = 1693 . | P* . | Validation data set FHCRC, N = 580 . |
|---|---|---|---|---|---|
| Sex, n (%) | |||||
| Male | 1052 (57.5) | 82 (60.7) | 970 (57.3) | .44 | 319 (55.0) |
| Ethnicity/race, n (%) | |||||
| Non-Hispanic white | 1142 (62.5) | 93 (68.9) | 1049 (62) | 502 (86.6) | |
| Hispanic | 453 (24.8) | 22 (16.3) | 431 (25.5) | 41 (7.1) | |
| Other | 233 (12.7) | 20 (14.8) | 213 (12.6) | .06 | 37 (6.4) |
| Age, y† | |||||
| Median (range) | 45.0 (1.6-79.9) | 53.0 (17.0-79.9) | 44.2 (1.6-78.3) | <.001 | 45.0 (2.0-74.0) |
| <30, n (%) | 407 (22.3) | 9 (6.7) | 398 (23.5) | 131 (22.6) | |
| 30 to <50, n (%) | 756 (41.4) | 46 (34.1) | 710 (41.9) | 98 (16.9) | |
| ≥50, n (%) | 665 (36.4) | 80 (59.3) | 585 (34.6) | <.001 | 351 (60.5) |
| Diagnosis, n (%) | |||||
| Acute leukemia | 537 (29.4) | 34 (25.2) | 503 (29.7) | 211 (36.4) | |
| Chronic leukemia | 241 (13.2) | 13 (9.6) | 228 (13.5) | 124 (21.4) | |
| Lymphoma | 704 (38.5) | 64 (47.4) | 640 (37.8) | 118 (20.3) | |
| Other | 346 (18.9) | 24 (17.8) | 322 (19.0) | .15 | 127 (21.9) |
| Anthracycline dose, mg/m2 | |||||
| Median (range) | 180 (0-1116) | 225 (0-528) | 180 (0-1116) | .001 | 116 (0-972) |
| ≤250 mg/m2, n (%) | 1183 (64.7) | 70 (51.9) | 1113 (65.7) | 409 (70.5) | |
| >250 mg/m2, n (%) | 645 (35.3) | 65 (48.1) | 580 (34.3) | .001 | 165 (28.4) |
| Anthracycline use, n (%) | |||||
| Yes | 1376 (75.3) | 111 (82.2) | 1265 (74.7) | .05 | 327 (56.4) |
| Chest radiation, n (%) | |||||
| Yes | 97 (5.3) | 11 (8.1) | 86 (5.1) | .13 | 47 (8.1) |
| HCT type, n (%) | |||||
| Autologous | 1031 (56.4) | 95 (70.4) | 936 (55.3) | 191 (32.9) | |
| Allogeneic | 797 (43.6) | 40 (29.6) | 757 (44.7) | .001 | 389 (67.1) |
| Conditioning regimen, n (%) | |||||
| Chemotherapy only | 850 (46.5) | 63 (46.7) | 787 (46.5) | 264 (45.5) | |
| Chemotherapy + TBI | 978 (53.5) | 72 (53.3) | 906 (53.5) | .97 | 314 (54.5) |
| Cardiovascular risk factors,†n (%) | |||||
| Hypertension | 512 (28.0) | 67 (49.6) | 445 (26.3) | <.001 | 136 (23.4) |
| Diabetes | 198 (10.8) | 37 (27.4) | 161 (9.5) | <.001 | 48 (8.3) |
| Dyslipidemia | 600 (32.8) | 52 (38.5) | 548 (32.4) | .14 | 36 (6.2) |
| Smoking, ever | 558 (30.5) | 59 (43.7) | 499 (29.5) | .001 | 217 (37.4) |
| Obesity (BMI ≥30 kg/m2) | 442 (24.2) | 41 (30.4) | 401 (23.7) | .081 | 114 (19.7) |